

Enzalutamide

ATC Code : L02BB04

【O8055】 Xtandi Soft Capsules 40 mg

中文名： 安可坦軟膠囊 40 毫克« Astellas »

適應症： 治療 1.藥物或手術去勢抗性的轉移性前列腺癌，且在雄性素去除療法失敗後屬無症狀或輕度症狀而不須使用化學治療者。2.藥物或手術去勢抗性的轉移性前列腺癌且已接受過 docetaxel 治療者。

藥理分類： Antineoplastic Agent, Antiandrogen.

用法用量： **Administration:**

Administer at the same time each day, either with or without food. Swallow capsules whole; do not chew, dissolve, or open the capsules.

**Indications and Dosage regimens:**

**Prostate cancer, castration-resistant:**

PO: 160 mg QD

**Dosage adjustment for concomitant strong CYP2C8 inhibitors:**

- Avoid concomitant use if possible.
- If coadministration is necessary, reduce enzalutamide dose to 80 mg once daily. If the strong CYP2C8 inhibitor is discontinued, adjust the enzalutamide dose back up to the dose used prior to the initiation of the strong CYP2C8 inhibitor.

**Dosage adjustment for concomitant strong CYP3A4 inducers:**

- Avoid concomitant use if possible.
- If coadministration is necessary, increase the enzalutamide dose to 240 mg once daily. If the strong CYP3A4 inducer is discontinued, adjust the enzalutamide dose back to the dose used prior to the initiation of the strong CYP3A4 inducer.

不良反應： 關節痛、便秘、腹瀉、水腫、眩暈。

交互作用： ※CYP2C8 and CYP3A4 are responsible for the metabolism of enzalutamide. ※※※ Enzalutamide is also a strong CYP3A4 inducer.

1. **strong CYP2C8 inhibitor (gemfibrozil)** : ↑ the plasma exposure of XTANDI.
2. **strong CYP3A4 inducers** (carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, St. John's wort): ↓ the plasma exposure of XTANDI.
3. Exemestane, fentanyl, sorafenib, warfarin, dronedarone, amiodarone, ticagrelor, linagliptin, erlotinib, tramadol, codeine, tamoxifen, imatinib, nifedipine, aprepitant, carbamazepine, rifabutin, phenytoin, hormonal contraceptives, voriconazole, ketoconazole, dihydroergotamine : ↓ the plasma exposure of these drugs. (Xtandi is also a **strong CYP3A4 inducer**)
4. **strong CYP3A4 inhibitor** (clarithromycin, voriconazole, ketoconazole) : ↑ the plasma exposure of XTANDI.

注意事項： 1.空腹或是飯後服用均可。整粒吞服，請勿咀嚼。  
2.孕婦勿用本品。服藥期間和服用最後一劑後的 3 個月內，請使用保險套及其他可靠的避孕方法。

懷孕期： 不得使用。

授乳期： 不得使用。

健保規定： ● 治療高風險轉移性的去勢敏感性前列腺癌(mCSPC)、藥物或手術去勢抗性的轉移性前列腺癌(mCRPC)、藥物或手術去勢抗性的轉移性前列腺癌，須經事前審查。

(摘要)

- 治療 mCRPC 時，與 abiraterone 僅能擇一使用。
- 治療 mCSPC 時，與 abiraterone、apalutamide 僅能擇一使用。(111/3/1)